Novartis Ag ADR (NVS)

$152.73 +1.93 (1.28%)
Market Cap 287.75B
Revenue (ttm) 56.67B
Net Income (ttm) 13.98B
EPS (ttm) N/A
PE Ratio 17.30
Forward PE 17.14
Profit Margin 24.67%
Debt to Equity Ratio 1.16
Volume 2,368,200
Avg Vol 1,812,458
Day's Range N/A - N/A
Shares Out 1.91B
Stochastic %K 37%
Beta 0.45
Analysts Sell
Price Target $147.86

Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CD...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 324 11 11
Fax: 41 61 324 78 26
Address:
Lichtstrasse 35, Basel, Switzerland
Merlintrader
Merlintrader Jul. 16 at 11:51 PM
REGENXBIO $RGNX Stock Hub - proposed 100 million dollar stock offering brings back dilution risk ahead of two Q3 2026 BLA paths (NAVSUNLI, RGX-202) and Q4 AbbVie retina data $ABBV $NVS https://www.merlintrader.com/regenxbio-stock-hub/
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 16 at 7:05 PM
$OTLK $REGN $NVS $BAYRY Good luck $OTLK #PDUFA 7/29/26! Is it #Bevacizumab’s hour almost? Nice dip! Some options expire on the 3rd Friday of the month, AKA, tomorrow? https://www.macular.org/wp-content/uploads/2026/02/2026-AMDF-Congressional-Report-3.pdf
0 · Reply
Quantumup
Quantumup Jul. 15 at 11:08 AM
Citizens⬆️ $CELC to $177, reiterated Market Outperform and said -- Celcuity's REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, won early approval and may be priced at a premium. $RLAY $NVS AZN PFE Citizens added—The approval, which came several days ahead of schedule, currently applies to only ER+/HER2- BC patients without PIK3CA mutations, based on results from VIKTORIA-1 Study 1. The sNDA for the PIK3CA-mutant population is expected in 3Q26. The FDA approval sets the stage for Celcuity's transition to a commercial-stage company. We remain optimistic, and view this as an additional buying opportunity ahead of a high potential launch; we look forward to further detail, including final price (at a premium). We maintain our Market Outperform rating and raise our DCF-derived price target to $177, from $160, by raising the PoS of Revtorpyk (gedatolisib) in the PI3K WT population to 100% following approval.
1 · Reply
Estimize
Estimize Jul. 14 at 10:03 PM
Wall St is expecting 2.17 EPS for $NVS Q2 [Reporting 07/21 BMO] http://www.estimize.com/intro/nvs?chart=historical&metric_name=eps&utm_cont
0 · Reply
BioTuesdays
BioTuesdays Jul. 14 at 8:20 PM
Closely held Myricx Bio has announced that it has reached an agreement to be acquired by Novartis $NVS for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. https://biotuesdays.com/2026/07/14/myricx-to-be-acquired-by-novartis-for-up-to-1-5b/
0 · Reply
grampslol
grampslol Jul. 11 at 7:44 AM
$MNKD watch out $UTHR $MRK $AMGN $NVS here's another week of afrezza dpi inhaled prandial insulin approved in 2014 scripts ... wk ending 7/3/26 New 328 refills 461 .... Lol
1 · Reply
clan
clan Jul. 11 at 6:25 AM
$UTHR subsequently paid a $5 million collaboration and development support payment to MannKind {$0.016/sh} in April 2026 [2Q26; to be reported on in 3 weeks]. $35M {$0.11/share} more to come $MNKD 's way. # Partners for life ... more humann❗️ � ​👀 $NVS $MRK $AMGN
1 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jul. 10 at 5:54 PM
$SLS $NVS M&A is getting crazy: Novartis Just Paid $1.1 billion in cash. Upfront. For a drug that has never entered a human trial. The real signal here is about timing, not science. A validated Phase 2 asset with this profile would cost several multiples of $1.5 billion total. Novartis paid a preclinical price to avoid an approved-asset price later. Everyone else in the room just watched the floor reset. GPS Regal Pivotal Registrational Phase 3 Study Paradigm shifting Top Line data = $120.00+ before BO! 🙏✌️❤️‍🩹
0 · Reply
JFais
JFais Jul. 9 at 1:56 PM
$NVS paying $1.1B upfront for Myricx Bio's unique NMTi payload platform, yet another ADC buyout. Lead targets are by no means novel (BY-H3 and HER2). Objective is to address narrow therapeutic window and tolerability challenges of predecessors including TOPO-1 and tubulin inhibitor payload classes. Makes me think of hidden value in $BHVN's novel ADC platform with lead targets TROP2 and FGFR3 (differentiated TOPO1x payload, so far no ILD observed & also low rates of heme toxicities and diarrhea vs peers). Hope they partner it out at some point (or even 50/50 co-develop deal)
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 9 at 11:03 AM
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next $SRPT $NVS $IJR $XBI https://stocktwits.com/news/equity/markets/srpt-stock-bullish-upgrade-novartis-readthrough-other-catalysts/cZmovIpR7nb
0 · Reply
Latest News on NVS
KVS, NVS, EMRS Tier-II Results Delayed? Candidates Demand Official Update

2026-07-15T02:34:47.000Z - 2 days ago

KVS, NVS, EMRS Tier-II Results Delayed? Candidates Demand Official Update

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Thu, 09 Jul 2026 12:12:04 -0400 - 7 days ago

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger

Wed, 08 Jul 2026 12:36:02 -0400 - 8 days ago

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger

Novartis Buys Myricx Bio in Up to $1.5 Billion Cancer Drug Deal

2026-07-06T13:47:08.000Z - 10 days ago

Novartis Buys Myricx Bio in Up to $1.5 Billion Cancer Drug Deal

Novartis Acquires Myricx Bio for Up to $1.5 Billion

2026-07-06T11:31:03.000Z - 10 days ago

Novartis Acquires Myricx Bio for Up to $1.5 Billion

Novartis (NVS) to Acquire Myricx Bio for Up to $1.5 Billion

2026-07-06T10:50:58.000Z - 10 days ago

Novartis (NVS) to Acquire Myricx Bio for Up to $1.5 Billion

Novartis (NVS) Expands Oncology Pipeline with Myricx Bio Acquisition

2026-07-06T10:50:36.000Z - 10 days ago

Novartis (NVS) Expands Oncology Pipeline with Myricx Bio Acquisition

Novartis to Acquire Myricx Bio for $1.5B to Boost Cancer Drugs; NVS Stock Falls

2026-07-06T10:48:05.000Z - 10 days ago

Novartis to Acquire Myricx Bio for $1.5B to Boost Cancer Drugs; NVS Stock Falls

Novartis agrees to acquire Myricx Bio for up to $1.5B

2026-07-06T09:30:13.000Z - 10 days ago

Novartis agrees to acquire Myricx Bio for up to $1.5B

Novartis to acquire Myricx Bio for $1.1B upfront

2026-07-06T09:25:16.000Z - 10 days ago

Novartis to acquire Myricx Bio for $1.1B upfront

Novartis Buys Myricx Bio in $1.5 Billion Deal

2026-07-06T09:24:01.000Z - 10 days ago

Novartis Buys Myricx Bio in $1.5 Billion Deal

Novartis (NVS) to Acquire Myricx Bio for Up to $1.5B to Enhance Oncology Pipeline

2026-07-06T08:56:18.000Z - 10 days ago

Novartis (NVS) to Acquire Myricx Bio for Up to $1.5B to Enhance Oncology Pipeline

Novartis To Acquire Myricx Bio In Deal Valued Up To $1.5 Bln, Expand Oncology Pipeline

2026-07-06T07:40:48.000Z - 10 days ago

Novartis To Acquire Myricx Bio In Deal Valued Up To $1.5 Bln, Expand Oncology Pipeline

Novartis to Buy Myricx Bio for Up to $1.5 Billion

Jul 6, 2026, 1:52 AM EDT - 10 days ago

Novartis to Buy Myricx Bio for Up to $1.5 Billion

NVS

Aussie super funds hit the jackpot in $2b biotech deal

2026-07-06T05:38:09.000Z - 10 days ago

Aussie super funds hit the jackpot in $2b biotech deal

Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

Jul 6, 2026, 1:26 AM EDT - 10 days ago

Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

NVS

Novartis AG (NVS) Stock Up 3.7% but GF Value Says Overvalued -- GF Score: 82/100

2026-07-02T22:20:58.000Z - 14 days ago

Novartis AG (NVS) Stock Up 3.7% but GF Value Says Overvalued -- GF Score: 82/100

Novartis (NVS) Gains EU Approval for Itvisma Gene Therapy for SMA

2026-07-02T19:56:49.000Z - 14 days ago

Novartis (NVS) Gains EU Approval for Itvisma Gene Therapy for SMA

Novartis (NVS) Secures Approval for Itvisma in SMA Treatment

2026-07-02T11:51:22.000Z - 14 days ago

Novartis (NVS) Secures Approval for Itvisma in SMA Treatment

Novartis receives EC approval for Itvisma for spinal muscular atrophy

2026-07-02T10:30:34.000Z - 14 days ago

Novartis receives EC approval for Itvisma for spinal muscular atrophy

Novartis Granted EC Approval For Itvisma In Treating Spinal Muscular Atrophy

2026-07-02T06:18:47.000Z - 14 days ago

Novartis Granted EC Approval For Itvisma In Treating Spinal Muscular Atrophy

Novartis Announces Approval Of Itvisma In Europe For Spinal Muscular Atrophy

2026-07-02T05:33:32.000Z - 14 days ago

Novartis Announces Approval Of Itvisma In Europe For Spinal Muscular Atrophy

3 European Stocks to Carry Investors Through the Back Half of 2026

Wed, 01 Jul 2026 11:05:28 -0400 - 15 days ago

3 European Stocks to Carry Investors Through the Back Half of 2026

The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell

2026-06-26T09:26:00.000Z - 20 days ago

The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell

Top Stock Reports for JPMorgan, Novartis & Qualcomm

2026-06-25T20:33:00.000Z - 21 days ago

Top Stock Reports for JPMorgan, Novartis & Qualcomm

Novartis Eyes $5 Billion Pluvicto Opportunity

2026-06-25T10:09:50.000Z - 21 days ago

Novartis Eyes $5 Billion Pluvicto Opportunity

Novartis Targets Hard-to-Treat Cancers

2026-06-24T16:35:47.000Z - 22 days ago

Novartis Targets Hard-to-Treat Cancers

Pre-Market Most Active for Jun 24, 2026 : WEN, NOK, ABSI, RUN, SQQQ, SPCX, CCXI, NVS, NIO, INFQ, AMC, SMR

2026-06-24T12:29:56.000Z - 22 days ago

Pre-Market Most Active for Jun 24, 2026 : WEN, NOK, ABSI, RUN, SQQQ, SPCX, CCXI, NVS, NIO, INFQ, AMC, SMR

Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis

Jun 24, 2026, 8:15 AM EDT - 22 days ago

Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis

NVS

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies

Jun 24, 2026, 7:00 AM EDT - 22 days ago

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies

NVS

Zacks Investment Ideas feature highlights: IBB, Novartis, Pfizer and Eli Lilly's

2026-06-24T08:28:00.000Z - 22 days ago

Zacks Investment Ideas feature highlights: IBB, Novartis, Pfizer and Eli Lilly's

The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs

Jun 19, 2026, 7:52 AM EDT - 27 days ago

The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs

AZN NVS

U.S. opens tariff probe targeting Germany's drug pricing policies

Jun 19, 2026, 4:47 AM EDT - 27 days ago

U.S. opens tariff probe targeting Germany's drug pricing policies

AZN NVS

Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

Jun 16, 2026, 1:00 AM EDT - 4 weeks ago

Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

ARKG IBB XBI GSK NUVL NVS

Novartis announces Rhapsido met primary endpoints in RemIND trial

2026-06-12T11:01:07.000Z - 4 weeks ago

Novartis announces Rhapsido met primary endpoints in RemIND trial

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Jun 12, 2026, 5:36 AM EDT - 4 weeks ago

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

NVS

Novartis says rare muscle disease drug shows promise in early trial

Jun 11, 2026, 5:41 PM EDT - 5 weeks ago

Novartis says rare muscle disease drug shows promise in early trial

NVS

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 5 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE JNJ

Novartis announces biomarker cohort in study of del-brax met primary endpoint

2026-06-11T10:47:32.000Z - 5 weeks ago

Novartis announces biomarker cohort in study of del-brax met primary endpoint

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

Jun 11, 2026, 1:00 AM EDT - 5 weeks ago

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

NVS

Novartis, Orionis enter collaboration for molecular glue medicines

2026-06-10T11:13:11.000Z - 5 weeks ago

Novartis, Orionis enter collaboration for molecular glue medicines

Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines

Jun 10, 2026, 7:00 AM EDT - 5 weeks ago

Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines

NVS

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Jun 8, 2026, 3:00 AM EDT - 5 weeks ago

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

NVS

Novartis reports final 2.5-year Phase III ALIGN results on Vanrafia

2026-06-04T10:30:58.000Z - 6 weeks ago

Novartis reports final 2.5-year Phase III ALIGN results on Vanrafia

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

Jun 4, 2026, 6:15 AM EDT - 6 weeks ago

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

NVS

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

Jun 3, 2026, 11:30 AM EDT - 6 weeks ago

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

NVS

Novartis announces 144-week data from ASC4FIRST trial of Scemblix

2026-06-01T11:46:51.000Z - 6 weeks ago

Novartis announces 144-week data from ASC4FIRST trial of Scemblix

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

Jun 1, 2026, 1:15 AM EDT - 6 weeks ago

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

NVS

Novartis announces results on rPFS improvements across subgroups with Pluvicto

2026-05-31T21:50:07.000Z - 6 weeks ago

Novartis announces results on rPFS improvements across subgroups with Pluvicto

Experimental Novartis radiopharma drug shows promise in early study

May 31, 2026, 7:16 AM EDT - 6 weeks ago

Experimental Novartis radiopharma drug shows promise in early study

NVS

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

May 31, 2026, 1:15 AM EDT - 6 weeks ago

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

May 26, 2026, 1:15 AM EDT - 7 weeks ago

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

May 21, 2026, 1:15 AM EDT - 2 months ago

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

US Supreme Court rebuffs pharma challenge to Biden-era drug price

May 18, 2026, 9:44 AM EDT - 2 months ago

US Supreme Court rebuffs pharma challenge to Biden-era drug price

AZN BMY NVO

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

May 17, 2026, 3:30 PM EDT - 2 months ago

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

Health Rounds: Common ADHD medicines help treat cancer-related fatigue

May 15, 2026, 7:04 AM EDT - 2 months ago

Health Rounds: Common ADHD medicines help treat cancer-related fatigue

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

May 7, 2026, 9:00 AM EDT - 2 months ago

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Novartis to cut 220 jobs as it closes German site

May 5, 2026, 8:16 AM EDT - 2 months ago

Novartis to cut 220 jobs as it closes German site

UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies

Apr 29, 2026, 5:32 AM EDT - 2 months ago

UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies

GSK

Novartis CEO warns of reality of Trump's drug pricing policy

Apr 28, 2026, 1:04 PM EDT - 2 months ago

Novartis CEO warns of reality of Trump's drug pricing policy

Novartis AG Earnings Call Transcript: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Novartis AG Earnings Call Transcript: Q1 2026

Novartis AG Earnings release: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Novartis AG Earnings release: Q1 2026

Novartis AG Quarterly report: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Novartis AG Quarterly report: Q1 2026

Novartis AG Slides: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Novartis AG Slides: Q1 2026

Novartis shares fall after weak Q1 hit by Entresto competition

Apr 28, 2026, 4:58 AM EDT - 2 months ago

Novartis shares fall after weak Q1 hit by Entresto competition

Novartis CEO: We knew these first two quarters would be bumpy

Apr 28, 2026, 3:54 AM EDT - 2 months ago

Novartis CEO: We knew these first two quarters would be bumpy

Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'

Apr 28, 2026, 3:23 AM EDT - 2 months ago

Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'

European markets to open higher as Trump considers Iran peace proposal

Apr 28, 2026, 1:18 AM EDT - 2 months ago

European markets to open higher as Trump considers Iran peace proposal

BCS BP

Novartis Q1 profit down on US generic erosion

Apr 28, 2026, 1:12 AM EDT - 2 months ago

Novartis Q1 profit down on US generic erosion

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Apr 28, 2026, 1:00 AM EDT - 2 months ago

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Novartis AG Slides: Investor presentation

Apr 28, 2026, 1:00 AM EDT - 2 months ago

Novartis AG Slides: Investor presentation

Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs

Apr 27, 2026, 12:55 PM EDT - 2 months ago

Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs

AMGN LLY

Novartis receives European Commission approval for Rhapsido skin disease drug

Apr 27, 2026, 1:31 AM EDT - 2 months ago

Novartis receives European Commission approval for Rhapsido skin disease drug

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Apr 27, 2026, 1:15 AM EDT - 2 months ago

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

Apr 24, 2026, 1:15 AM EDT - 2 months ago

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMs

Apr 15, 2026, 10:00 AM EDT - 3 months ago

Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMs

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Apr 9, 2026, 1:15 AM EDT - 3 months ago

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Mar 29, 2026, 1:15 AM EDT - 3 months ago

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

Mar 27, 2026, 7:43 AM EDT - 3 months ago

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

Novartis to Buy Biotech Excellergy for Up to $2 Billion

Mar 27, 2026, 2:33 AM EDT - 3 months ago

Novartis to Buy Biotech Excellergy for Up to $2 Billion

Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion

Mar 27, 2026, 2:28 AM EDT - 3 months ago

Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

Mar 27, 2026, 2:05 AM EDT - 3 months ago

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Mar 27, 2026, 2:00 AM EDT - 3 months ago

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

Mar 23, 2026, 2:15 AM EDT - 4 months ago

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 4 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

ABBV AMRX OGN

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

Mar 20, 2026, 2:33 AM EDT - 4 months ago

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

Novartis to buy breast cancer drug candidate from Synnovation

Mar 20, 2026, 2:25 AM EDT - 4 months ago

Novartis to buy breast cancer drug candidate from Synnovation

Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Kα Inhibitor Program

Mar 20, 2026, 2:05 AM EDT - 4 months ago

Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Kα Inhibitor Program

Merlintrader
Merlintrader Jul. 16 at 11:51 PM
REGENXBIO $RGNX Stock Hub - proposed 100 million dollar stock offering brings back dilution risk ahead of two Q3 2026 BLA paths (NAVSUNLI, RGX-202) and Q4 AbbVie retina data $ABBV $NVS https://www.merlintrader.com/regenxbio-stock-hub/
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 16 at 7:05 PM
$OTLK $REGN $NVS $BAYRY Good luck $OTLK #PDUFA 7/29/26! Is it #Bevacizumab’s hour almost? Nice dip! Some options expire on the 3rd Friday of the month, AKA, tomorrow? https://www.macular.org/wp-content/uploads/2026/02/2026-AMDF-Congressional-Report-3.pdf
0 · Reply
Quantumup
Quantumup Jul. 15 at 11:08 AM
Citizens⬆️ $CELC to $177, reiterated Market Outperform and said -- Celcuity's REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, won early approval and may be priced at a premium. $RLAY $NVS AZN PFE Citizens added—The approval, which came several days ahead of schedule, currently applies to only ER+/HER2- BC patients without PIK3CA mutations, based on results from VIKTORIA-1 Study 1. The sNDA for the PIK3CA-mutant population is expected in 3Q26. The FDA approval sets the stage for Celcuity's transition to a commercial-stage company. We remain optimistic, and view this as an additional buying opportunity ahead of a high potential launch; we look forward to further detail, including final price (at a premium). We maintain our Market Outperform rating and raise our DCF-derived price target to $177, from $160, by raising the PoS of Revtorpyk (gedatolisib) in the PI3K WT population to 100% following approval.
1 · Reply
Estimize
Estimize Jul. 14 at 10:03 PM
Wall St is expecting 2.17 EPS for $NVS Q2 [Reporting 07/21 BMO] http://www.estimize.com/intro/nvs?chart=historical&metric_name=eps&utm_cont
0 · Reply
BioTuesdays
BioTuesdays Jul. 14 at 8:20 PM
Closely held Myricx Bio has announced that it has reached an agreement to be acquired by Novartis $NVS for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. https://biotuesdays.com/2026/07/14/myricx-to-be-acquired-by-novartis-for-up-to-1-5b/
0 · Reply
grampslol
grampslol Jul. 11 at 7:44 AM
$MNKD watch out $UTHR $MRK $AMGN $NVS here's another week of afrezza dpi inhaled prandial insulin approved in 2014 scripts ... wk ending 7/3/26 New 328 refills 461 .... Lol
1 · Reply
clan
clan Jul. 11 at 6:25 AM
$UTHR subsequently paid a $5 million collaboration and development support payment to MannKind {$0.016/sh} in April 2026 [2Q26; to be reported on in 3 weeks]. $35M {$0.11/share} more to come $MNKD 's way. # Partners for life ... more humann❗️ � ​👀 $NVS $MRK $AMGN
1 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jul. 10 at 5:54 PM
$SLS $NVS M&A is getting crazy: Novartis Just Paid $1.1 billion in cash. Upfront. For a drug that has never entered a human trial. The real signal here is about timing, not science. A validated Phase 2 asset with this profile would cost several multiples of $1.5 billion total. Novartis paid a preclinical price to avoid an approved-asset price later. Everyone else in the room just watched the floor reset. GPS Regal Pivotal Registrational Phase 3 Study Paradigm shifting Top Line data = $120.00+ before BO! 🙏✌️❤️‍🩹
0 · Reply
JFais
JFais Jul. 9 at 1:56 PM
$NVS paying $1.1B upfront for Myricx Bio's unique NMTi payload platform, yet another ADC buyout. Lead targets are by no means novel (BY-H3 and HER2). Objective is to address narrow therapeutic window and tolerability challenges of predecessors including TOPO-1 and tubulin inhibitor payload classes. Makes me think of hidden value in $BHVN's novel ADC platform with lead targets TROP2 and FGFR3 (differentiated TOPO1x payload, so far no ILD observed & also low rates of heme toxicities and diarrhea vs peers). Hope they partner it out at some point (or even 50/50 co-develop deal)
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 9 at 11:03 AM
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next $SRPT $NVS $IJR $XBI https://stocktwits.com/news/equity/markets/srpt-stock-bullish-upgrade-novartis-readthrough-other-catalysts/cZmovIpR7nb
0 · Reply
justiceforb_85
justiceforb_85 Jul. 9 at 2:27 AM
$GLUE intrigued by MRT-6160. Do they have a favorable partnership on this with $NVS?
2 · Reply
Bobear12
Bobear12 Jul. 7 at 7:22 PM
$NVS why doesn’t NVS buy GALT before Lilly LLY does? Bo-wants to know
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 7 at 12:36 PM
What would $NVS pay for $RADX
0 · Reply
Bobear12
Bobear12 Jul. 6 at 7:07 PM
$NVS we hit the back stretch and they are running on green grass. GALT has maintained the lead and widen the lead over NVS. The bad news is NVS will be out of the money. Bo-is- sad.
0 · Reply
Quantumup
Quantumup Jul. 6 at 6:46 PM
Piper Sandler reiterated $TNYA Overweight; $40 and said ~ TN-301 Not Yet Valued But Can Become a Key Value Driver for TNYA $NVS CYTK BMY $TENX TECX CAPR SRPT DYN RNA Here's what else Piper Sandler had to say: https://x.com/Quantumup1/status/2074203088450142598?s=20
0 · Reply
Bobear12
Bobear12 Jul. 6 at 5:35 PM
$NVS red vs green NVS is Red vs GALT is Green. NVS needs to buy GALT. Bo- is ready for the - purchase.
0 · Reply
NodeNebula
NodeNebula Jul. 6 at 2:09 PM
$NVS is set to acquire UK cancer biotech Myricx Bio for up to $1.5B. Clear strategic add-on for the oncology pipeline, and the deal size signals real conviction. Market will likely watch for fit, execution, and whether this changes the growth story.
0 · Reply
prismmarketview
prismmarketview Jul. 6 at 1:16 PM
$NVS Novartis is doubling down on oncology — a $1.5B deal to acquire UK biotech Myricx Bio for its next-gen ADC cancer platform, plus a fresh research partnership with Antares Therapeutics. Here's what it means for the pipeline and the stock 🧵 #Novartis #Oncology #Biotech #MandA #PharmaNews https://prismmarketview.com/novartis-myricx-bio-acquisition-oncology/
0 · Reply
DonCorleone77
DonCorleone77 Jul. 6 at 10:21 AM
$NVS Novartis agrees to acquire Myricx Bio for up to $1.5B Novartis announced that it has entered into an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company developing a new class of antibody-drug conjugates, using N-myristoyltransferase inhibitor payloads. "The proposed acquisition would strengthen the Novartis oncology pipeline and advance next-generation targeted drug conjugates with novel payload mechanisms. Myricx's approach is designed to deliver a differentiated cancer-killing payload directly to tumor cells, with the potential to address limitations of commonly used ADC payload classes such as TOPO-1 inhibitors. Myricx is developing two lead assets directed towards the targets B7-H3 and HER2, with potential across multiple solid tumor settings," the company stated. Under the terms of the agreement, Novartis will pay $1.1B upfront, with up to $400M in potential milestone payments to acquire Myricx Bio. The transaction is expected to close in the second half of 2026, subject to the satisfaction or waiver of customary closing conditions, including regulatory approvals.
0 · Reply
notreload_ai
notreload_ai Jul. 6 at 10:10 AM
$NVS will pay $1.1B upfront for Myricx Bio, gaining B7-H3 and HER2 ADCs with innovative NMTi technology designed to overcome cancer resistance. https://notreload.xyz/xy/novartis-to-acquire-myricx-bio-to-bolster-next-gen-adc-pipeline/
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 6 at 2:18 AM
Learn about the top radiopharmaceutical companies reshaping oncology with groundbreaking therapies and a robust pipeline of innovations. Source: PharmaShots $RADX $LLY $NVS https://pharmashots.com/31777/top-20-radiopharmaceutical-companies-of-2026/
0 · Reply
Danzzzzzzzz
Danzzzzzzzz Jul. 2 at 3:51 PM
$BMY $LLY $NVS $PNT $RYZB
0 · Reply